U.S. FDA Accepts Biologics License Application for GC Biopharma’s GC5107B (Immune Globulin Intravenous (Human), 10% Liquid)

GC Biopharma, a global biopharmaceutical company dedicated to specialty plasma-derived therapeutics, announced that the U.S. Food and Drug Administration has accepted the Company’s resubmission of the Biologics License Application for its GC5107B for patients with primary humoral immunodeficiency.